Compare Innovative Industrial Properties Inc (IIPR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Summit Therapeutics Inc — how do they compare? Innovative Industrial Properties Inc trades at $62.59 (market cap $1.87B), while Summit Therapeutics Inc trades at $14.43 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 5.6× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 11.81% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| IIPR | SMMT | |
|---|---|---|
Market Cap | $1.87B | $10.48B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $29.32 |
52-Week Low | $44.58 | $13.05 |
Enterprise Value | $2.25B | $9.90B |
Dividend Yield | 11.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $64.35, down slightly today, amid a bullish technical trend with strong moving average support. The REIT reported mixed quarterly earnings, with a significant beat in Q4 2025 but a miss in Q1 2026, while maintaining a high dividend yield. Recent news highlights successful debt management and cannabis rescheduling progress as positive catalysts.
Outlook is cautiously optimistic given the strong balance sheet and regulatory tailwinds, but risks include revenue volatility and high dividend payout. Analyst sentiment is mixed with a slight Hold bias, reflecting concerns over near-term earnings consistency versus long-term growth potential in the cannabis real estate sector.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
